Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences announced the grant of stock options to newly hired employees effective July 6, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Coherus BioSciences announced the grant of stock options to newly hired employees effective July 6, 2021. A total of 221,500 shares were allocated, with a per share exercise price set at $13.63, matching the closing price on the grant date. Notably, a newly appointed Vice President received options for 45,000 shares. This action is part of the Company's 2016 Employment Commencement Incentive Plan, aimed at incentivizing new talent to join the organization.
Positive
- Granting of stock options may enhance employee retention and motivation.
- The compensation committee's decision reflects the company's confidence in its growth and recruitment strategy.
Negative
- None.
Details
News Market Reaction – CHRS
The recorded move for CHRS in the trading session of this news was -0.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 6, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 221,500 shares of the common stock of the Company to newly hired employees with a per share exercise price of
The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. For additional information, please visit www.coherus.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.